台灣臨床試驗主持人資料庫|TPIDB

2015-09-15 - 2019-02-28

Phase II

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Condition/Disease

Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Test Drug

Ramucirumab

Participate Sites
6Sites

Terminated5Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源

China Medical University Hospital-Taipei

未分科

2015-08-14 - 2024-05-01

Phase III

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Condition/Disease

Non-Small Cell Lung Cancer (NSCLC)
Test Drug

Ramucirumab

Participate Sites
10Sites

Recruiting5Sites

Terminated4Sites

羅永鴻

Taipei Veterans General Hospital

夏德椿

China Medical University Hospital-Taipei

未分科

2017-09-21 - 2020-12-31

Phase III

An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

Condition/Disease

Advanced Breast Cancer
Test Drug

Ribociclib (LEE011)/ Letrozole/Goserelin

Participate Sites
6Sites

Terminated5Sites

鍾為邦

National Taiwan University Hospital

Division of Hematology & Oncology

邱昌芳

China Medical University Hospital-Taipei

未分科

2017-12-01 - 2019-12-31

Phase III

Multi-center, partially blinded, randomized, 24-week, parallel grouping, non-inferiority, open-label, active controlled trial, comparing the efficacy and safety of QVM149 with salmeterol/fluticasone + tiotropium triple combination therapy for patients with poorly controlled asthma

Condition/Disease

Asthma
Test Drug

QVM149

Participate Sites
9Sites

Terminated7Sites

許超群

Kaohsiung Municipal Gangshan Hospital

未分科

杭良文

China Medical University Hospital-Taipei

未分科

2017-05-01 - 2020-03-04

Phase II

A randomized, double blind, placebo controlled multicenter Phase 2 doseranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjögren’s syndrome

Condition/Disease

Sjögren’s syndrome
Test Drug

VAY736

Participate Sites
7Sites

Terminated5Sites

藍忠亮

China Medical University Hospital

藍忠亮

China Medical University Hospital-Taipei

未分科

2016-09-30 - 2019-12-31

Phase II

A randomised, double-blind, placebo-controlled, proof-of-concept, dose-ranging study of BI 655066 in patients with active psoriatic arthritis

Condition/Disease

Active psoriatic arthritis
Test Drug

BI655066

Participate Sites
9Sites

Terminated7Sites

賴建志

Taipei Veterans General Hospital

Division of Rheumatology

黃春明

China Medical University Hospital-Taipei

未分科

2017-01-01 - 2020-06-30

Phase III

A Phase 3 Multicenter, Randomized, Double-blind,Placebo-controlled Study with an Open Label Extension to Evaluatethe Efficacy and Safety of KHK4827 in Subjects with Axial Spondyloarthritis

Condition/Disease

Axial Spondyloarthritis
Test Drug

KHK4827 (Brodalumab)

Participate Sites
13Sites

Terminated11Sites

羅淑芬

Linkou Chang Gung Medical Foundation

黃春明

China Medical University Hospital-Taipei

未分科

Search Result

List